Evidence map›Paper›PMID 33828310›Full record

ArticleScientific reports2021

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and

Shiliang Huang, Joel E Michalek, David A Reardon, Patrick Y Wen, John R Floyd, Peter T Fox, Geoffrey D Clarke, Paul A Jerabek, Kathleen M Schmainda, Mark Muzi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Biomaterial-basedCancer pathogenesis and therapy · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. [Neuro-oncology practice · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Shiliang HuangMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
Joel E MichalekMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
David A ReardonDana-Farber Cancer Institute, Boston, MA, USA.
Patrick Y WenDana-Farber Cancer Institute, Boston, MA, USA.
John R FloydMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
Peter T FoxMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
Geoffrey D ClarkeMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
Paul A JerabekMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
Kathleen M SchmaindaDepartments of Radiology and Biophysics, Medical College of Wisconsin, Wauwatosa, WI, USA.
Mark MuziDepartment of Radiology, University of Washington, Seattle, WA, USA.
Hyewon HyunDivision of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Eudocia Quant LeeDana-Farber Cancer Institute, Boston, MA, USA.
Andrew J BrennerMays Cancer Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA. dr_brenner@yahoo.com.
The University of Texas Health Science Center at San Antonio · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USMedical College of Wisconsin · USUniversity of Washington · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Core Laboratory for Advanced PET and MRI image analysisR50CA211270 · NCI · UNIVERSITY OF WASHINGTON · PI Mark Muzi · 2017 to 2026
$2.6M
Phase 2 Study of TH-302 for the Treatment of GlioblastomaR01FD004400 · FDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BRENNER, ANDREW JACOB · 2014 to 2020
$1.8M
FDA HHSFDA HHS R01 FD004400NCI NIH HHS P30 CA054174NCI NIH HHS R50 CA211270
6 · The paper itself

Abstract

Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify those with recurrent GBM who may benefit from evofosfamide, we ascertained MRI features and hypoxia in patients with GBM progression receiving both agents. Thirty-three patients with recurrent GBM refractory to bevacizumab were enrolled. Patients underwent MR and

Indexed as

AdultAgedBevacizumabBiomarkers, PharmacologicalBrain NeoplasmsCerebral Blood VolumeDrug Resistance, NeoplasmFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedMisonidazoleNeoplasm Recurrence, LocalPositron-Emission TomographyBevacizumabBiomarkers, PharmacologicalfluoromisonidazoleMisonidazole

Identifiers

PMID33828310
PMCPMC8027395
OpenAlexW3152397551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.